Penumbra Profit Margin 2014-2022 | PEN

Current and historical gross margin, operating margin and net profit margin for Penumbra (PEN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Penumbra net profit margin as of June 30, 2022 is -2.4%.
Penumbra Annual Profit Margins
Penumbra Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $6.619B $0.748B
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $236.833B 24.12
Edwards Lifesciences (EW) United States $64.933B 45.94
Alcon (ALC) Switzerland $34.110B 28.88
STERIS (STE) Ireland $21.399B 26.58
Teleflex (TFX) United States $11.944B 19.03
Fresenius Medical Care AG KGaA (FMS) Germany $10.930B 10.08
Globus Medical (GMED) United States $6.721B 34.28
Integer Holdings (ITGR) United States $2.525B 19.75
Glaukos (GKOS) United States $2.496B 0.00
Nevro (NVRO) United States $1.877B 0.00
Paragon 28 (FNA) United States $1.568B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.400B 21.44
Artivion (AORT) United States $0.937B 89.42